必须声明标量变量 "@Script_ID"。 Anakinra对急性痛风的作用机制与治疗研究进展-《赣南医学院学报》

[1]饶 嘉,陈 楠,李成江.Anakinra对急性痛风的作用机制与治疗研究进展[J].赣南医学院学报,2019,39(10):1003-1006+1021.[doi:10.3969/j.issn.1001-5779.2019.10.007]
 RAO Jia,CHEN Nan,LI Cheng-jiang.Progress in the mechanism and treatment of Anakinra on acute gout[J].,2019,39(10):1003-1006+1021.[doi:10.3969/j.issn.1001-5779.2019.10.007]
点击复制

Anakinra对急性痛风的作用机制与治疗研究进展()
分享到:

《赣南医学院学报》[ISSN:1001-5779/CN:36-1154/R]

卷:
39
期数:
2019年10期
页码:
1003-1006+1021
栏目:
炎症与免疫·基础与临床
出版日期:
2019-11-24

文章信息/Info

Title:
Progress in the mechanism and treatment of Anakinra on acute gout
文章编号:
1001-5779(2019)10-1003-05
作者:
饶 嘉1陈 楠2李成江1
1.浙江大学医学院附属第一医院内分泌科,浙江 杭州 310003; 2.中山大学附属第八医院内分泌科,广东 深圳 518033
Author(s):
RAO Jia1 CHEN Nan2 LI Cheng-jiang1
1.Department of Endocrinology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003; 2.Department of Endocrinology, the Eighth Affiliated Hospital, College of Medicine, Zhongshan University, Shenzhen, Guangdong 518033
关键词:
阿那白滞素 白介素-1 急性痛风 单钠尿酸盐
Keywords:
anakinra IL-1 acute gout MSU
分类号:
R589.7
DOI:
10.3969/j.issn.1001-5779.2019.10.007
文献标志码:
A
摘要:
急性痛风是一种常见的自身炎症性关节炎,由滑膜关节软组织内单钠尿酸盐(monosodium urate, MSU)晶体沉积引起,尿酸盐通过半胱天冬酶(caspase)激活单核巨噬细胞分泌白细胞介素-1β(interleukin-1β,IL-1β),从而介导痛风性炎症反应。由于痛风常见的一些合并症,目前首选治疗药物的使用受到许多限制。2016年更新的欧洲风湿病防治联合会(European League Against Rheumatism, EULAR)指南建议对急性痛风频繁发作以及难以使用常规疗法治疗的患者使用IL-1受体拮抗剂(interleukin-1 receptor antagonist, IL-1Ra)。阿那白滞素(anakinra)是一种重组非糖基化的人IL-1Ra,目前已被美国食品药品管理局(FDA)批准上市,并用于治疗类风湿关节炎等疾病多年,相比于其他IL-1Ra,anakinra的性价比更高。近年来anakinra治疗急性痛风的研究日益增多,研究结果支持其在治疗急性痛风发作中的有效性。本文就其对急性痛风的作用与治疗研究作一综述。
Abstract:
Acute gout is a common form of autoinflammatory inflammatory arthritis caused by crystal deposition of monosodium urate(MSU)in the synovial joint soft tissue.Urate mediates gout inflammatory response by caspase activating the cytokine interleukin-1β(IL-1β).There are many treatment options for gout, but due to some common complications of gout, the use of currently preferred treatments is subject to many restrictions.The 2016 European Union Against Rheumatism(EULAR)guidelines recommend the use of interleukin-1(IL-1)in patients with frequent episodes of acute gout and in patients who are difficult to treat with conventional therapy.Body antagonist treatment.IL-1 inhibitors are clinically useful for the treatment of autoinflammatory diseases, arthritis, gout, stroke, diabetes and its complications, tumors, etc.Anakinra is a recombinant, non-glycosylated the human interleukin-1 receptor antagonist(IL-1Ra), currently approved by the US Food and Drug Administration(FDA), is used to treat other diseases such as rheumatoid arthritis for many years and is compared to other IL-1 Body antagonists, anakinra is more cost-effective.In recent years, anakinra has been increasing the number of studies on acute gout and has made some progress.Previous data and clinical case reports support its effectiveness in acute and subacute gout attacks.This article summarizes the mechanism and treatment progress of Anakinra on acute gout.

参考文献/References:

[1] Roddy E, Doherty M.Epidemiology of gout[J].Arthritis Research & Therapy, 2010, 12(6):223.
[2] Cronstein BN, Sunkureddi P.Mechanistic Aspects of Inflammation and Clinical Management of Inflammation in Acute Gouty Arthritis[J].Jcr-Journal of Clinical Rheumatology, 2013, 19(1):19-29.
[3] Chandratre P, Roddy E, Clarson L, et al.Health-related quality of life in gout: a systematic review[J].Rheumatology, 2013, 52(11):2031-2040.
[4] ten Klooster PM, Vonkeman HE, van de Laar MAFJ.Disability due to gouty arthritis[J].Current Opinion in Rheumatology, 2012, 24(2):139-144.
[5] Janssens H, Janssen M, van de Lisdonk EH, et al.Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial[J].Lancet, 2008, 371(9627):1854-1860.
[6] Richette P, Doherty M, Pascual E, et al.2016 updated EULAR evidence-based recommendations for the management of gout[J].Annals of the Rheumatic Diseases, 2017, 76(1):29-42.
[7] Wechalekar MD, Vinik O, Moi JHY, et al.The Efficacy and Safety of Treatments for Acute Gout: Results from a Series of Systematic Literature Reviews Including Cochrane Reviews on Intraarticular Glucocorticoids, Colchicine, Nonsteroidal Antiinflammatory Drugs, and Interleukin-1 Inhibitors[J].Journal of Rheumatology, 2014, 41(92):15-25.
[8] Pascart T, Liote F.Gout: state of the art after a decade of developments[J].Rheumatology, 2019, 58(1):27-44.
[9] Martinon F, Petrilli V, Mayor A, et al.Gout-associated uric acid crystals activate the NALP3 inflammasome[J].Nature, 2006, 440(7081):237-241.
[10] Cavalli G, Dinarello CA.Anakinra Therapy for Non-cancer Inflammatory Diseases[J].Front Pharmacol, 2018, 9:1157.
[11] Dinarello CA, Ikejima T, Warner SJ, et al.Interleukin 1 induces interleukin 1.I.Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro[J].J Immunol, 1987, 139(6):1902-1910.
[12] Martinon F, Mayor A, Tschopp J.The inflammasomes: guardians of the body[J].Annu Rev Immunol, 2009, 27:229-265.
[13] Hoffman HM, Wanderer AA.Inflammasome and IL-1beta-mediated disorders[J].Curr Allergy Asthma Rep, 2010, 10(4):229-235.
[14] Arend WP, Joslin FG, Massoni RJ.Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor[J].J Immunol, 1985, 134(6):3868-3875.
[15] Prieur AM, Kaufmann MT, Griscelli C, et al.Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis[J].Lancet, 1987, 2(8570):1240-1242.
[16] Seckinger P, Lowenthal JW, Williamson K, et al.A urine inhibitor of interleukin 1 activity that blocks ligand binding[J].J Immunol, 1987, 139(5):1546-1549.
[17] Hannum CH, Wilcox CJ, Arend WP, et al.Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor[J].Nature, 1990, 343(6256):336-340.
[18] Keenan RT, O'Brien WR, Lee KH, et al.Prevalence of contraindications and prescription of pharmacologic therapies for gout[J].Am J Med, 2011, 124(2):155-163.
[19] Schlesinger N, Alten RE, Bardin T, et al.Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions[J].Annals of the Rheumatic Diseases, 2012, 71(11):1839-1848.
[20] Terkeltaub RA, Schumacher HR, Carter JD, et al.Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator[J].Arthritis Research & Therapy, 2013, 15(1):R25.
[21] Janssen CA, Oude Voshaar MAH, Vonkeman HE, et al.Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial[J].Rheumatology(Oxford, England), 2019, 58:1344-1352.
[22] Liew JW, Gardner GC.Use of Anakinra in Hospitalized Patients with Crystal-associated Arthritis[J].The Journal of rheumatology, 2019, 46(10):1345-1349.
[23] Desmarais J, Chu CQ.Utility of Anakinra in Acute Crystalline Diseases: A Retrospective Study Comparing a University Hospital with a Veterans Affairs Medical Center[J].Journal of Rheumatology, 2019, 46(7):748-750.
[24] Loustau C, Rosine N, Forien M, et al.Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study[J].Joint Bone Spine, 2018, 85(6):755-760.

备注/Memo

备注/Memo:
作者简介:饶嘉,女,硕士研究生,研究方向:尿酸与核受体研究。E-mail:jiaraojx@gmail.com
通信作者:李成江,男,硕士,教授,主任医师,研究方向:代谢综合征及糖尿病大血管病变研究。E-mail:hzcili03@zju.edu.cn
更新日期/Last Update: 2019-11-20